The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Survival benefits of warfarin in Korean patients with idiopathic pulmonary arterial hypertension

  • Kang, Byung Ju (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Oh, Yeon-Mok (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-Do (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jae Seung (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2014.11.17
  • Accepted : 2014.12.22
  • Published : 2015.11.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Idiopathic pulmonary arterial hypertension (IPAH) is an incurable disease with high mortality. Although most studies recommend anticoagulation treatment for IPAH, the benefits are uncertain, particularly in Korea, where it has not been studied. The purpose of this study was to evaluate survival outcomes of Korean patients with IPAH treated with warfarin. Methods: We performed a retrospective cohort study of patients diagnosed previously with pulmonary arterial hypertension (PAH) at the Asan Medical Center in Korea, between January 1994 and February 2013. We excluded patients with associated PAH, patients who did not undergo right heart catheterization (RHC), and patients with a positive vasoreactivity test. Patients in the study cohort were classified into a "warfarin group" and a "non-warfarin group," according to the treatment they received during the first year after diagnosis. Results: We identified 31 patients with IPAH and a negative vasoreactivity test on RHC. Median patient age was 36.0 years, and 23 patients (74.2%) were female. The median time from the onset of symptoms to diagnosis was 19.0 months, and the most common presenting symptom was dyspnea. Survival rates of the patients at 1, 3, 5, and 10 years were 90.2%, 79.5%, 62.7%, and 34.8%, respectively. The mean survival period was 12.0 years in the warfarin group and 6.1 years in the nonwarfarin group. Warfarin treatment had significant survival benefits in patients with IPAH (p = 0.023). Conclusions: Warfarin treatment substantially improved survival outcomes in Korean cases of IPAH.

Keywords

References

  1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-D41. https://doi.org/10.1016/j.jacc.2013.10.029
  2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349. https://doi.org/10.7326/0003-4819-115-5-343
  3. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006;130:545-552. https://doi.org/10.1016/S0012-3692(15)51873-4
  4. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994;150:929-933. https://doi.org/10.1164/ajrccm.150.4.7921465
  5. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-587. https://doi.org/10.1161/01.CIR.70.4.580
  6. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81. https://doi.org/10.1056/NEJM199207093270203
  7. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 1993;57:63-69. https://doi.org/10.1253/jcj.57.63
  8. Roman A, Rodes-Cabau J, Lara B, et al. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension. Med Clin (Barc) 2002;118:761-766. https://doi.org/10.1016/S0025-7753(02)72524-4
  9. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005;95:199-203. https://doi.org/10.1016/j.amjcard.2004.09.006
  10. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014;129:57-65. https://doi.org/10.1161/CIRCULATIONAHA.113.004526
  11. Storstein O, Efskind L, Muller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand 1966;179:197-212.
  12. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-721. https://doi.org/10.1378/chest.112.3.714
  13. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-488. https://doi.org/10.1161/01.CIR.93.3.484
  14. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136. https://doi.org/10.1164/ajrccm.152.3.7663792
  15. Park JO, Choi IS, Park KO. Normal predicted values of single-breath diffusing capacity of the lung in healthy nonsmoking adults. Korean J Intern Med 1986;1:178-184. https://doi.org/10.3904/kjim.1986.1.2.178
  16. Standardization of lung function testing in infants, children and adolescents. Paediatric Working Group, Cefalu, Palermo, October 4, 1982. Abstracts. Bull Eur Physiopathol Respir 1983;19:15P-24P.
  17. Quinones MA, Waggoner AD, Reduto LA, et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981;64:744-753. https://doi.org/10.1161/01.CIR.64.4.744
  18. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463. https://doi.org/10.1016/j.echo.2005.10.005
  19. Shiran H, Zamanian RT, McConnell MV, et al. Relationship between echocardiographic and magnetic resonance derived measures of right ventricular size and function in patients with pulmonary hypertension. J Am Soc Echo-cardiogr 2014;27:405-412. https://doi.org/10.1016/j.echo.2013.12.011
  20. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985;6:750-756. https://doi.org/10.1016/S0735-1097(85)80477-0
  21. Chemla D, Castelain V, Humbert M, et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004;126:1313-1317. https://doi.org/10.1378/chest.126.4.1313
  22. Ikeda D, Tsujino I, Sakaue S, et al. Pilot study of shortterm effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007;71:1829-1831. https://doi.org/10.1253/circj.71.1829
  23. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223. https://doi.org/10.7326/0003-4819-107-2-216
  24. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007;132:373-379. https://doi.org/10.1378/chest.06-2913
  25. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999;39:847-854. https://doi.org/10.1177/00912709922008380
  26. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030. https://doi.org/10.1164/rccm.200510-1668OC
  27. Tueller C, Stricker H, Soccal P, et al. Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly 2008;138:379-384.
  28. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376-387. https://doi.org/10.1378/chest.09-1140

Cited by

  1. Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension? : A Systematic Review and Meta-Analysis vol.11, pp.9, 2015, https://doi.org/10.1161/circoutcomes.118.004757